Progression factors for chronic kidney disease. Secondary prevention;Factores de progresión de la enfermedad renal crónica. Prevención secundaria

Nefrologia

Volumn 28, Issue SUPPL. 3, 2008, Pages 17-21

  De Vinuesa, S García ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chronic kidney disease; Progression; Vascular risk factors

Indexed keywords

EID: 51349130045     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsciker LG, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
2. Peterson JC, Adler S, Burkart JM, Greene T, Hebert IA, Hunsciker LG, for the Modification of Diet in Renal Disease (MDRD) Study Group: blood pressure control, proteinuria, and the progression of renal diseae. Ann Inter Med 1995; 123: 754-762.
3. Hunsciker LG, Adler S, Caggiula AW, England BK, Greene T, Kusek JW. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51:1908-1919.
4. Luño J, García de Vinuesa S, Gómez Campderá F, Lorenzo I, Rodriguez P, D'Allanese C, Rodriguez A, Valderrábano F. Factores pronósticos en la progresión de la enfermedad renal. Nefrologia 1999; 19 (6): 523-531.
5. Haroun Mk, Jaar BG, Hoffman SC y cols. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington country. J Am Soc Nephrol 2003; 14: 2934-2941.
6. The Diabetes Control and Complications in Insulin-Dependent Diabetes Mellitus. Effect of Intensive treatment of diabetes on the development and progresión of long-temr complications in insuline-dependent diabetes mellitus. New Engl J Med 1993; 329 (14): 979-986.
7. Hannedouche, T, Albouze, G, Chauveau, P y cols. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. Am J Kidney Dis 1993; 21: 131-135.
8. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsuceh W, Sowers J. Preserving renal function in adult with hypertension and diabetes: a consensus approach, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
9. Lhotta K, Rumpelt HU, Konig P y cols. Cigarrette smoking and vascular pathology In renal biopsies. Kidney Int 2002; 61: 648-654.
10. Morales E, Valero MA, León M y cols. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.
11. GISEN. Randomized placebo-controlled trial effects of ramipril on decline In glomerular filtration rate and risk of terminal renal failure In proteinuric, non-diabetic nephropatjy. Lancet 1997; 349: 1857-1863
12. Jafar, TH, Stark PC, Schmid, CH, Landa, M, Maschio G, De Jong PE, De Zeeuw D, Shahinfar S, Toto R, Levey AS. AIPRD Study Group: The role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
13. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P: The effect of irbesartan on the development of diabetic nephropathy in patients with tipe 2 diabetes. N Eng J Med 2001; 345: 870-878.
14. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345 (12): 861-869.
15. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-860.
16. Hillege HL, Fidler V, Diercks GFH, Van Gilst WH, De Zeeuw D, Van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE, De Jong PE for the PREVEND Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
17. Gansevoort RT, Sluiter WJ, Hemmelder MH, De Zeeuw D, De Jong PE: Antiproteinuric effect of blood-pressure-lowering agent: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974.
18. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J for the Diabetics Exposed to telmisartan and enalapril Study Group: angiotensin-receptor blockade versus convertingenzyme inhibitiion in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
19. Nakao N, Yosimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II recceptor blocker and angiotensin-converting-enzyme inhibitor in non diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
20. Palla R, Panichi V, Finato V, Parrini M, Andreini B, Bianchi AM, Giovannini L, Migliori M, Bertelli AA. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with lgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994; 14 (1): 35-43.
21. Luño J, Barrio V, Goicoechea M, González C, García de Vinuesa S, Gómez F. Efects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2003; 62 (Supl. 82): S47-S52.
22. Bianchi S, Bigazzi R, Campese VM. Long-term of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney lnt 2006; 70: 2116-2123.
23. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers on nephropathy progression. Kidney Int 2004; 65 (6): 1991-2002.